Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Stewart
D J
DJ
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
Evans
W K
WK
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage; D000818:Animals; D000963:Antimetabolites / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019328:Buthionine Sulfoximine; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002147:Calmodulin / Q000037:antagonists & inhibitors; D002316:Cardiotonic Agents / Q000008:administration & dosage; D002648:Child; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000008:administration & dosage; D004341:Drug Evaluation; D004351:Drug Resistance; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage; D008297:Male; D008717:Methionine Sulfoximine / Q000008:administration & dosage / Q000031:analogs & derivatives; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009593:Nitroimidazoles / Q000008:administration & dosage; D014970:Xanthines / Q000008:administration & dosage
D000963:Antimetabolites; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D002147:Calmodulin; D002316:Cardiotonic Agents; D009593:Nitroimidazoles; D014970:Xanthines; D008717:Methionine Sulfoximine; C008514:methylxanthine; D019328:Buthionine Sulfoximine; D004176:Dipyridamole; D000666:Amphotericin B; D007654:Ketoconazole